Skip to content
LATEST
Health

Merck’s Phase 3 pembrolizumab lung cancer trial reaches completion

The registry update makes KEYNOTE-671 results available for review in resectable Stage II, IIIA and IIIB non-small cell lung cancer.

Merck's Phase 3 pembrolizumab lung cancer trial reaches completion

Merck Sharp & Dohme LLC's Phase 3 KEYNOTE-671 trial of pembrolizumab with platinum doublet chemotherapy for resectable non-small cell lung cancer was listed as completed on ClinicalTrials.gov on Nov. 20.

The clinical trial registry record matters because Phase 3 studies are late-stage tests of efficacy and safety, and this record targets Stage II, IIIA and IIIB (T3-4N2) disease rather than metastatic cancer.

KEYNOTE-671, also identified as NCT03425643, evaluated pembrolizumab as neoadjuvant and adjuvant therapy, meaning treatment used before and after the main local treatment. The chemotherapy backbone included platinum doublet chemotherapy with cisplatin, gemcitabine and pemetrexed, according to the registry record.

The trial focused on resectable non-small cell lung cancer, the most common broad category of lung cancer. Resectable disease refers to cancer considered suitable for surgical removal, although eligibility in a trial depends on protocol criteria.

Completion of a trial does not by itself establish benefit or risk. The significance for patients and clinicians depends on the posted efficacy and safety results, including survival outcomes, adverse events and how the pembrolizumab-containing regimen compared with the control approach.

Merck Sharp & Dohme LLC sponsored the study.

Source: clinical trial registry, ClinicalTrials.gov, Nov. 20, 2026

Atlas360 reports health research and does not provide medical advice.

More stories

Latest news